Novartis sheds generics plant and 450 jobs amid pricing pressure
pharmafile | October 18, 2017 | News story | Manufacturing and Production, Research and Development | Novartis, US, closure, generics, manufacturing, pharma
Novartis has announced its intention to shut down its US generics manufacturing plant in Broomfield, Colorado, a move that will lead to a loss of 450 jobs over a two-year period.
According to the company, the decision was made due pricing pressures in as a result of “double-digit price erosion caused by customer consolidation and increased competition taking place within the US generic drug market”.
Drug ingredient operation from the closed Broomfield facility will be transferred to another of the company’s plants in Wilson, North Carolina.
“With several products no longer competitive in saturated markets, we have made the decision to discontinue or divest these limited growth products to optimize our product portfolio,” explained Sandoz spokesman Tim Willeford. “As a result, we will consolidate commercial production of our generic solids portfolio at our Wilson, North Carolina manufacturing site and close commercial production operations at our Broomfield, Colorado manufacturing site.
“They show limited growth, are expensive to make, and are in a highly competitive market where other treatment options exist. Combined with increasing pricing pressures in the US, it is not profitable to continue making these products,” he added.
The facility, operated under the firm’s Sandoz division, is one of 40 under that name and a total of 67 under the wider company, comprising 133,400 staff worldwide. 24 or these locations are in the US, employing over 23,000 people. Sandoz has announced that it will offer severance packages to those affected along with job placement assistance.
Willeford continued: “As part of our global strategy, we consolidated all drug manufacturing operations into a new organisational model with the aim of optimizing capacity planning, improving efficiency and allowing for better resource allocation, creating a fit-for-purpose network for long term, profitable growth. To achieve this goal, we are continually reviewing our manufacturing network to ensure we have an organisational structure that meets patient demand requirements, and to improve its competitiveness.”
Matt Fellows
Related Content
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
